Drug General Information (ID: DDILA73ZWB)
  Drug Name Clofazimine Drug Info Ondansetron Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiinflammatory Agents Antiemetics
  Structure

 Mechanism of Clofazimine-Ondansetron Interaction (Severity Level: Moderate)
     Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Clofazimine Ondansetron
      Mechanism Prolong QT interval Prolong QT interval
      Key Mechanism Factor 1
Factor Name QT interval
Factor Description Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
      Mechanism Description
  • Increased risk of prolong QT interval by the combination of Clofazimine and Ondansetron 

Recommended Action
      Management Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval. Consider monitoring electrocardiograms, particularly in patients receiving clofazimine dosages greater than 100 mg/day, and discontinue QT-prolonging medications if clinically significant ventricular arrhythmia is noted or if QTcF interval >=500 ms is observed. If syncope occurs, obtain an ECG to detect QT prolongation.

References
1 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.